Boxlight Launches CL Totem in North America, Providing Modern, Freestanding Digital Signage Built for High-Traffic Environments
Boxlight Corporation (Nasdaq: BOXL) —recognized as one of the top ed-tech companies in the world for innovative solutions that enhance communication and collaboration in educational institutions and businesses—is expanding its lineup of professional signage solutions with the CL Totem, now available in North America. This modern, freestanding display offers a simple and effective way to share information in high-traffic spaces, with no need for mounting, subscriptions or complex setup.
Available in 49" and 55", the CL Totem brings together bold visuals, modern design and effortless content management in one self-contained, freestanding unit. Built for high-traffic environments like retail stores, hotel lobbies, restaurants and corporate campuses, the CL Totem delivers high-impact messaging—without the complexity of traditional signage systems.
'What makes the CL Totem so exciting is that it delivers the kind of polished, high-impact signage experience that organizations have been asking for—without the setup headaches or recurring costs,' said Daniel Morris, Boxlight's Category Manager – Displays (Americas) and Director of Enterprise & Government Sales. 'It's a sleek, professional display that works right out of the box, with the flexibility to adapt to retail, hospitality or public spaces.'
Unique features of the CL Totem:
This launch marks another step in Boxlight's strategy to unify its digital signage and interactive display offerings under a common platform, giving customers a streamlined, scalable visual communication solution.
The CL Totem is now available. To learn more, visit boxlight.com.
About Boxlight Corporation
Boxlight Corporation (Nasdaq: BOXL) is a leading provider of interactive technology solutions under its award-winning brands Clevertouch ®, FrontRow™ and Mimio ®. The Company aims to improve engagement and communication in diverse business and education environments. Boxlight develops, sells and services its integrated solution suite including interactive displays, collaboration software, audio solutions, supporting accessories, and professional services. For more information about Boxlight and the Boxlight story, visit http://www.boxlight.com and http://www.clevertouch.com and https://www.gofrontrow.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250605670393/en/
CONTACT: Media Contact
[email protected]
+1 360-464-2119Investor Relations
[email protected]
+1 360-464-4478
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: SOFTWARE AUDIO/VIDEO HARDWARE PROFESSIONAL SERVICES TECHNOLOGY PRIMARY/SECONDARY EDUCATION BUSINESS
SOURCE: Boxlight Corporation
Copyright Business Wire 2025.
PUB: 06/05/2025 09:11 AM/DISC: 06/05/2025 09:10 AM
http://www.businesswire.com/news/home/20250605670393/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital's petition against 1Globe Capital LLC ('1Globe') for relief relating to SINOVAC's shareholder votes and corporate governance. In its ruling, the Court concluded, 'relief relating to governance outcomes or shareholder votes – are DENIED without prejudice.' The Massachusetts ruling marks the fourth unsuccessful legal attempt by either Advantech/Prime Success ('Advantech/Prime') or Vivo Capital (together 'the Dissenting Investor Group') to strip SINOVAC common shareholders of their rightful dividend payments. This result follows Advantech/Prime's recently failed petition in New York and Advantech/Prime and Vivo Capital's recently failed petition in Hong Kong – which were repeated attempts to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the Company's payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. The Dissenting Investor Group continues to interfere with the current Board's fiduciary duties to implement the UK Privy Council's unappealable ruling in January 2025. In this ruling, the UK Privy Council deemed the former illegitimate board an 'Imposter Board' and handed 1Globe – the investment arm of a cancer-focused global R&D group and SINOVAC's largest shareholder – a victory on all grounds. In addition, the UK Privy Council Judicial Committee, comprising five UK Supreme Court Justices, concluded that there was 'nothing unlawful in the conduct of 1Globe' in connection with SINOVAC's 2018 AGM. The Dissenting Investor Group's self-serving, multi-pronged lawfare strategy is crystal clear: (1) block actions taken by the SINOVAC Board to distribute rightful dividend payments to valid SINOVAC common shareholders; (2) protect the ill-gotten gains it stripped from SINOVAC subsidiaries over the past seven years; and (3) regain control of SINOVAC in order to continue to loot the Company. Having failed in the courtroom, the Dissenting Investor Group has decided to instead use deceptive and false stories to attack 1Globe and its founder Dr. Chiang Li, who chairs the current SINOVAC Board. As noted in SINOVAC's proxy materials, Dr. Li is an accomplished clinician, scientist, inventor, entrepreneur and a seasoned executive with international recognitions. Dr. Li and 1Globe have successfully challenged the Dissenting Investor Group's abuse in court for the past seven years and championed the rights and interests of all valid SINOVAC shareholders. During those seven years, The Dissenting Investor Group, in coordination with the former illegitimate board (the 'Imposter Former Board'), pursued the following schemes: Privatization attempt at a below-market price in 2016, which would have succeeded had it not been for the efforts of 1Globe (who declined an invite by the Former Management Buyout Group to join and profit from its privatization attempt); Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital; Commitment by the Imposter Former Board to invest ~US$139 million of SINOVAC cash into a venture fund managed by Vivo Capital – creating a clear conflict of interest. This would be in addition to the approximately US$100 million SINOVAC has already invested into Vivo Capital funds. US$15 million debt investment into Sinovac Life Sciences Co., Ltd. ('SLS'), a wholly owned subsidiary of SINOVAC, in exchange for a 15% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$1 billion of distributions made to the Dissenting Investor Group. In contrast, SINOVAC common shareholders have received no dividends and haven't been able to trade their shares for the past six years. To add insult to injury, the Imposter Former Board publicly stated in April 2024 in the Company's 2023 20-F that it had 'no plan to pay any cash dividends on SINOVAC Antigua's shares in the foreseeable future'; Barrage of baseless and wasteful legal action in 2025, after refusing to accept the Privy Council's non-appealable ruling, with the goal of interfering with the dividend payment unless the Dissenting Investor Group is able to double dip on dividends already received from SLS; Deceptive and disparaging campaign against current SINOVAC board members that is meant to intimidate them and interfere with the stability and function of the current Board. The Dissenting Investor Group's hostile actions, baseless claims and wasteful litigation are evidence that it poses a direct threat to the value of your investment and the future of SINOVAC. Don't let the Dissenting Investor Group, which is working in coordination with SAIF and is represented on SAIF's Reconstituted Imposter Former Board, regain control of the Company. If the Reconstituted Imposter Former Board succeeds, it will put all valid shareholders' future dividend payments at risk – this includes the current Board's announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares, and its adopted policy to issue regular dividends out of surplus cash. The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders. Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Business Wire
28 minutes ago
- Business Wire
of Amperio Project in Switzerland and Quitérios in Portugal
LIMOGES, France--(BUSINESS WIRE)--Regulatory News: Legrand (Paris:LR) is actively pursuing its targeted development strategy, with the announcement today of two new acquisitions. Amperio Project is a Swiss specialist in busbars. Based in Murten, the company employs around 20 people and has annual sales of over €4 million. Following Computer Room Solutions (CRS) in Australia and Linkk Busway Systems in Malaysia, Amperio Project is the third acquisition of the year in datacenters. Quitérios 1 is a leading Portuguese player in electrical and digital modular distribution boards. Based in Mira, the company employs more than 100 people and has annual sales of nearly €20 million. Benoît Coquart, Legrand's Chief Executive Officer; commented: 'We are very pleased with these two new acquisitions, which bring the number of transactions announced since the beginning of the year to five, for a total annual revenue of more than €100 million. These investments are fully in line with our strategic roadmap for 2030, which includes strengthening our positions in fast-growing segments related to the energy and digital transition.' Readers are invited to verify the authenticity of Legrand press releases with the CertiDox app. Learn more at Key financial dates : • 2025 first-half results : July 31, 2025 'Quiet period 2 ' starts : July 1, 2025 • 2025 nine months results : 'Quiet period 2 ' starts : October 7, 2025 Expand About Legrand Legrand is the global specialist in electrical and digital building infrastructures. Its comprehensive offering of solutions for residential, commercial, and datacenter markets makes it a benchmark for customers worldwide. The Group harnesses technological and societal trends with lasting impacts on buildings with the purpose of improving life by transforming the spaces where people live, work and meet with electrical, digital infrastructures and connected solutions that are simple, innovative and sustainable. Drawing on an approach that involves all teams and stakeholders, Legrand is pursuing a strategy of profitable and responsible growth driven by acquisitions and innovation, with a steady flow of new offerings that include products with enhanced value in use (energy and digital transition solutions: datacenters, digital lifestyles and energy transition offerings). Legrand reported sales of €8.6 billion in 2024. The company is listed on Euronext Paris and is a component stock of the CAC 40, CAC 40 ESG and CAC Transition Climat indexes. (code ISIN FR0010307819).
Business Wire
an hour ago
- Business Wire
Elliptic Labs Launches 12 Smartphone Models with vivo, Transsion, and HONOR for June 2025
OSLO, Norway--(BUSINESS WIRE)-- Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensors™ currently deployed in over half a billion devices, has shipped its AI Virtual Smart Sensor Platform™ on 12 smartphone models in June 2025. HONOR launched four smartphones: the HONOR 400 Series. vivo announced five smartphones: the vivo IQOO Neo10 Pro+ and S30 Series, the T4 Ultra, and the vivo Y400 Pro. Transsion announced three smartphones with Elliptic Labs: the Tecno POVA Curve and the Tecno POVA 7 Series. For 2025 year-to-date, Elliptic Labs has launched on a total of 36 smartphone models. 'Elliptic Labs' AI Virtual Smart Sensor Platform was launched on 12 smartphone models in June 2025, bringing our total to 36 smartphone model launches year-to-date 2025,' said Laila Danielsen, CEO of Elliptic Labs. Share 'Elliptic Labs' AI Virtual Smart Sensor Platform was launched on 12 smartphone models in June 2025, bringing our total to 36 smartphone model launches year-to-date 2025,' said Laila Danielsen, CEO of Elliptic Labs. AI Virtual Proximity Sensor INNER BEAUTY Elliptic Labs' AI Virtual Proximity Sensor detects when a user holds their phone up to their ear during a call, allowing the smartphone to turn off its display and disable its screen's touch functionality. This keeps the user's ear or cheek from triggering unwanted actions during the call, such as hanging up or dialing numbers. Turning off the screen also helps conserve battery life. Proximity detection is a core capability that is used in all smartphones, but Elliptic Labs' AI Virtual Proximity Sensor is a unique, software-only solution that delivers robust proximity detection without the need for a dedicated hardware sensor. By replacing hardware sensors with software sensors, the AI Virtual Proximity Sensor reduces device cost and eliminates sourcing risk. INNER BEAUTY is a registered trademark of Elliptic Labs. AI Virtual Smart Sensor, AI Virtual Proximity Sensor, and AI Virtual Smart Sensor Platform are trademarks of Elliptic Labs. All other trademarks or service markets are the responsibility of their respective organizations. About Elliptic Labs Elliptic Labs' AI Virtual Smart Sensor Platform™ brings contextual intelligence to devices, enhancing user experiences. Our technology uses proprietary deep neural networks to create AI-powered Virtual Smart Sensors that improve personalization, privacy, and productivity. Currently deployed in over 500 million devices, our platform works across all devices, operating systems, platforms, and applications. By utilizing system-level telemetry data to cloud-based Large Language Models (LLMs), the AI Virtual Smart Sensor Platform delivers the unrivaled capability to utilize output data from every available data source. This approach allows devices to better understand and respond to their environment, making technology more intuitive and user-friendly. At Elliptic Labs, we're not just adapting to the future of technology – we're actively shaping it. Our goal is to continue pushing the boundaries of contextual intelligence, creating more intuitive and powerful experiences for users worldwide. Elliptic Labs is headquartered in Norway with presence in the USA, China, South-Korea, Taiwan, and Japan. The company is listed on the Oslo Stock Exchange. Its technology and IP are developed in Norway and are solely owned by the company.
